Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...

With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world.

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – ...

Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...

The Federal Trade Commission Friday announced it was suing the country's three biggest pharmacy benefit managers, claiming ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

Deutsche Bank analyst James Shin has maintained their bullish stance on LLY stock, giving a Buy rating on September 16. James Shin has given ...

Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled in one of the biggest medical controversies in recent years. For their ...

Collaboration between giant pharmaceutical corporations and patients with very little power just doesn’t work, according to ...

Healthcare technology company ResMed 's (NYSE: RMD) stock wasn't quite the picture of health on Wednesday. The shares lost more than 5% of their value on news of an analyst's downgrade and his new, ...

Two new papers by a team of researchers at Boston University, the Indiana University School of Medicine and the Alzheimer’s Disease Neuroimaging Initiative (ADNI), and the German Center for ...

Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...